Heart:SVT患者接受辅助医务人员治疗很安全!

2017-09-26 王淳 环球医学

2017年9月,发表在《Heart》的一项由英国科学家进行的随机对照试验,考察了定期阵发性室上性心动过速患者接受辅助医务人员治疗的安全性和有效性。



2017年9月,发表在《Heart》的一项由英国科学家进行的随机对照试验,考察了定期阵发性室上性心动过速患者接受辅助医务人员治疗的安全性和有效性。

介绍:阵发性室上性心动过速(SVT)是紧急入院的常见原因。腺苷是一种有效的治疗方法。至今,没有研究直接比较腺苷治疗的急性SVT患者的辅助医务人员治疗vs医院提供治疗。

方法:比较辅助医务人员SVT治疗和出院vs基于传统急诊的治疗的随机对照试验。将具有结构性心脏病或对腺苷禁忌的患者排除。研究人员比较了出院时间、随访管理、成本和患者满意度。

结果:纳入86例患者:44例随机分配到辅助医务人员驱动的腺苷(PARA)组,42例分配到常规治疗(ED)组。PARA组给予腺苷的37例患者中,81%成功终止了心动过速。辅助医务人员的ECG诊断与两名电生理医生的ECG诊断具有98%的相关性。两组没有患者发生不良事件。PARA组比ED组的出院时间短(125分(范围55~9513)vs 222分(72~26153),P=0.01),该治疗策略具有更大成本效果(£282 vs £423,P=0.01)。多数患者更倾向于该管理方法。辅助医务人员治疗和出院并不影响患者接受心律失常和心脏病随访持续管理的可能性。

结论:SVT患者能有效和安全地接受经过培训的辅助医务人员传递的腺苷治疗。实施辅助医务人员传递的急性SVT治疗具有降低医疗成本而不影响患者治疗的潜力。

原始出处

Honarbakhsh S, Baker V, Kirkby C, et al. Safety and efficacy of paramedic treatment of regular supraventricular tachycardia: a randomised controlled trial. Heart. 2017 Sep;103(18):1413-1418. doi: 10.1136/heartjnl-2016-309968. Epub 2016 Sep 9.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043689, encodeId=d8a62043689b8, content=<a href='/topic/show?id=41031695484' target=_blank style='color:#2F92EE;'>#SVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16954, encryptionId=41031695484, topicName=SVT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sat Jun 16 08:47:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303257, encodeId=a1e0130325e2c, content=<a href='/topic/show?id=b7853394932' target=_blank style='color:#2F92EE;'>#医务人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33949, encryptionId=b7853394932, topicName=医务人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356520, encodeId=6bca135652055, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562703, encodeId=232e1562e033d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247909, encodeId=d5de24e90945, content=射频消融治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Sep 26 15:18:33 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-06-16 花花1366

    #SVT#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2043689, encodeId=d8a62043689b8, content=<a href='/topic/show?id=41031695484' target=_blank style='color:#2F92EE;'>#SVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16954, encryptionId=41031695484, topicName=SVT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sat Jun 16 08:47:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303257, encodeId=a1e0130325e2c, content=<a href='/topic/show?id=b7853394932' target=_blank style='color:#2F92EE;'>#医务人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33949, encryptionId=b7853394932, topicName=医务人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356520, encodeId=6bca135652055, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562703, encodeId=232e1562e033d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247909, encodeId=d5de24e90945, content=射频消融治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Sep 26 15:18:33 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-28 charleshjw
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043689, encodeId=d8a62043689b8, content=<a href='/topic/show?id=41031695484' target=_blank style='color:#2F92EE;'>#SVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16954, encryptionId=41031695484, topicName=SVT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sat Jun 16 08:47:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303257, encodeId=a1e0130325e2c, content=<a href='/topic/show?id=b7853394932' target=_blank style='color:#2F92EE;'>#医务人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33949, encryptionId=b7853394932, topicName=医务人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356520, encodeId=6bca135652055, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562703, encodeId=232e1562e033d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247909, encodeId=d5de24e90945, content=射频消融治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Sep 26 15:18:33 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-28 zhaojie88

    #ART#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2043689, encodeId=d8a62043689b8, content=<a href='/topic/show?id=41031695484' target=_blank style='color:#2F92EE;'>#SVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16954, encryptionId=41031695484, topicName=SVT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sat Jun 16 08:47:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303257, encodeId=a1e0130325e2c, content=<a href='/topic/show?id=b7853394932' target=_blank style='color:#2F92EE;'>#医务人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33949, encryptionId=b7853394932, topicName=医务人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356520, encodeId=6bca135652055, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562703, encodeId=232e1562e033d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247909, encodeId=d5de24e90945, content=射频消融治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Sep 26 15:18:33 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-28 slcumt

    #HEART#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2043689, encodeId=d8a62043689b8, content=<a href='/topic/show?id=41031695484' target=_blank style='color:#2F92EE;'>#SVT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16954, encryptionId=41031695484, topicName=SVT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sat Jun 16 08:47:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303257, encodeId=a1e0130325e2c, content=<a href='/topic/show?id=b7853394932' target=_blank style='color:#2F92EE;'>#医务人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33949, encryptionId=b7853394932, topicName=医务人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356520, encodeId=6bca135652055, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562703, encodeId=232e1562e033d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Sep 28 05:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247909, encodeId=d5de24e90945, content=射频消融治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Sep 26 15:18:33 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 楠博One

    射频消融治疗

    0

相关资讯

Stroke:阵发性室上性心动过速与缺血性卒中独立相关

  美国一项研究表明,阵发性室上性心动过速(PSVT)与缺血性卒中呈独立相关,PSVT可能为卒中的新型危险因素。论文4月30日在线发表于《卒中》(Stroke)。   此项回顾性队列研究利用急诊和住院保险索赔资料确认了相关患者。主要暴露指标为卒中发生前或卒中就诊时伴有PSVT诊断。排除伴有房颤诊断的患者亦减少混淆。利用ICD-9确定PSVT、卒中和房颤。   结果显示,共有4806830例适宜

阵发性室上性心动过速的确诊过程中需要注意什么?

本例患者为18岁男性,阵发性心悸2年。初诊考虑阵发性室上性心动过速,经一系列问诊及体格检查未发现异常,最后通过心电图和食管电生理印证初诊判断,最终诊断为慢-快型房室结折返性心动过速。本病例在如何发现诊断线索、鉴别心电图和选择治疗方案等方面具有代表性,详细要点请见下文。